TAM
LXRX icon

Telluride Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Telluride Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,864
Closed -$23K – 282
2013
Q4 		$23K Buy
+1,864
New +$29.7K 0.03% 188

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Telluride Asset Management's LXRX Position: Q1 2014 in Review

Telluride Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2014, closing a stake of 1,864 shares — an estimated $23K sold.

Telluride Asset Management first reported a position in LXRX in Q4 2013 and held it in 1 quarter. The position peaked at $23K in Q4 2013. 103 funds tracked by Wall St. Rank hold LXRX as of Q1 2014.

  • Telluride Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Telluride Asset Management sold 1,864 Lexicon Pharmaceuticals shares in Q1 2014, an estimated $23K.
  • Telluride Asset Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Telluride Asset Management's Lexicon Pharmaceuticals position peaked at $23K in Q4 2013.
  • 103 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2014.

Based on Telluride Asset Management's 13F filing for Q1 2014, filed 14 May 2014.